PuraPharm (HKSE:01498) EBIT per Share

: HK$-0.36 (TTM As of Jun. 2022)

View and export this data going back to 2015. Start your Free Trial

PuraPharm's EBIT per Share for the six months ended in Jun. 2022 was HK$-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 was HK$-0.36.

During the past 12 months, the average EBIT per Share Growth Rate of PuraPharm was -87.00% per year. During the past 3 years, the average EBIT per Share Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for PuraPharm's EBIT per Share or its related term are showing as below:

HKSE:01498' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -94.1 Med: -11.2 Max: 103.2
Current: 6.2

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of PuraPharm was 103.20% per year. The lowest was -94.10% per year. And the median was -11.20% per year.

HKSE:01498's 3-Year EBIT Growth Rate is ranked worse than
54.31% of 871 companies
in the Drug Manufacturers industry
Industry Median: 8.20 vs HKSE:01498: 6.20

PuraPharm's EBIT for the six months ended in Jun. 2022 was HK$-20.7 Mil.

PuraPharm EBIT per Share Historical Data

The historical data trend for PuraPharm's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

0.11

0.18

-0.73

0.18

-0.23

PuraPharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EBIT per Share													0.08	0.10	0.08	-0.31	-0.05

PuraPharm EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

PuraPharm's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-90.165	/	393.733
=	-0.23

PuraPharm's EBIT per Share for the quarter that ended in Jun. 2022 is calculated as

	EBIT per Share		(Q: Jun. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.705	/	394.109
=	-0.05

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.36

PuraPharm (HKSE:01498) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

PuraPharm EBIT per Share Related Terms

Thank you for viewing the detailed overview of PuraPharm's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

PuraPharm (HKSE:01498) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » EBIT per Share

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is primarily engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines